69C Stock Overview
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Cara Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.60 |
52 Week High | US$4.04 |
52 Week Low | US$0.44 |
Beta | 0.70 |
1 Month Change | -23.62% |
3 Month Change | 33.33% |
1 Year Change | -83.77% |
3 Year Change | -97.38% |
5 Year Change | -96.42% |
Change since IPO | -94.11% |
Recent News & Updates
Recent updates
Shareholder Returns
69C | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | -16.2% | -3.3% | -1.5% |
1Y | -83.8% | -30.8% | 0.9% |
Return vs Industry: 69C underperformed the German Pharmaceuticals industry which returned -31.3% over the past year.
Return vs Market: 69C underperformed the German Market which returned -0.4% over the past year.
Price Volatility
69C volatility | |
---|---|
69C Average Weekly Movement | 17.8% |
Pharmaceuticals Industry Average Movement | 6.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.0% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 69C's share price has been volatile over the past 3 months.
Volatility Over Time: 69C's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | 55 | Chris Posner | www.caratherapeutics.com |
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica.
Cara Therapeutics, Inc. Fundamentals Summary
69C fundamental statistics | |
---|---|
Market cap | €37.59m |
Earnings (TTM) | -€111.34m |
Revenue (TTM) | €19.70m |
1.9x
P/S Ratio-0.3x
P/E RatioIs 69C overvalued?
See Fair Value and valuation analysisEarnings & Revenue
69C income statement (TTM) | |
---|---|
Revenue | US$20.97m |
Cost of Revenue | US$113.55m |
Gross Profit | -US$92.58m |
Other Expenses | US$25.93m |
Earnings | -US$118.51m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -2.17 |
Gross Margin | -441.53% |
Net Profit Margin | -565.21% |
Debt/Equity Ratio | 65.0% |
How did 69C perform over the long term?
See historical performance and comparison